Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases

被引:12
|
作者
Sugiura, Ayumi [1 ]
Joshita, Satoru [1 ]
Yamashita, Yuki [1 ]
Yamazaki, Tomoo [1 ]
Fujimori, Naoyuki [1 ]
Kimura, Takefumi [1 ]
Matsumoto, Akihiro [1 ,2 ]
Wada, Shuichi [3 ]
Mori, Hiromitsu [3 ]
Shibata, Soichiro [3 ]
Yoshizawa, Kaname [4 ]
Morita, Susumu [4 ]
Furuta, Kiyoshi [5 ]
Kamijo, Atsushi [5 ]
Iijima, Akihiro [6 ]
Kako, Satoko [6 ]
Maruyama, Atsushi [7 ]
Kobayashi, Masakazu [8 ]
Komatsu, Michiharu [8 ]
Matsumura, Makiko [9 ]
Miyabayashi, Chiharu [10 ]
Ichijo, Tetsuya [11 ]
Takeuchi, Aki [12 ]
Koike, Yuriko [13 ]
Gibo, Yukio [14 ]
Tsukadaira, Toshihisa [15 ]
Inada, Hiroyuki [16 ]
Nakano, Yoshiyuki [17 ]
Usuda, Seiichi [18 ]
Kiyosawa, Kendo [18 ]
Tanaka, Eiji [19 ]
Umemura, Takeji [1 ,20 ]
机构
[1] Shinshu Univ, Dept Med, Div Gastroenterol & Hepatol, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[2] Shinshu Univ Hosp, Consultat Ctr Hepat Dis, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[3] Japanese Red Cross Soc Nagano Hosp, Dept Gastroenterol, 22-1 Wakasato, Nagano, Nagano 3800928, Japan
[4] Natl Hosp Org, Shinshu Ueda Med Ctr, Dept Gastroenterol, 27-21 Midorigaoka, Ueda, Nagano 3868610, Japan
[5] Natl Hosp Org, Matsumoto Med Ctr, Dept Gastroenterol, 20-30 Muraimachiminami, Matsumoto, Nagano 3998701, Japan
[6] Nagano Prefectural Kiso Hosp, Dept Internal Med, 6613-4 Fukushima, Kiso, Nagano 3978555, Japan
[7] Ina Cent Hosp, Dept Gastroenterol, 1313-1 Koshiroukubo, Ina, Nagano 3968555, Japan
[8] Japanese Red Cross Soc Suwa Hosp, Dept Gastroenterol, 5-11-50 Kogandori, Suwa, Nagano 3928510, Japan
[9] Nagano Chuo Hosp, Dept Gastroenterol, 1570 Tsuruga Nishitsurugamachi, Nagano, Nagano 3800814, Japan
[10] Chikuma Cent Hosp, Dept Gastroenterol, 58 Kuiseshita, Chikuma, Nagano 3870011, Japan
[11] Japanese Red Cross Soc Azumino Hosp, Dept Gastroenterol, 5685 Toyoshina, Azumino, Nagano 3998205, Japan
[12] Aki Naika Clin, 236-1 Nozawa, Saku, Nagano 3850053, Japan
[13] Kawanakajima Clin, 1942-25 Kawanagajima Machi, Nagano, Nagano 3812221, Japan
[14] Gibo Hepatol Clin, 1-34-20 Muraimachiminami, Matsumoto, Nagano 3990036, Japan
[15] Kenwakai Hosp, Dept Gastroenterol, 1936 Kanaenakadaira, Iida, Nagano 3958522, Japan
[16] Kanebako Internal Med Clin, 320-2 Kanebako, Nagano, Nagano 3810007, Japan
[17] Nakano Gastroenterol Clin, 4-13-5 Muraimachiminami, Matsumoto, Nagano 3990036, Japan
[18] Aizawa Hosp, Gastroenterol Ctr, 2-5-1 Honjo, Matsumoto, Nagano 3900814, Japan
[19] Shinshu Univ, Dept Community Med Promot, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[20] Shinshu Univ, Inst Biomed Sci, Dept Life Innovat, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
基金
日本学术振兴会;
关键词
chronic hepatitis C; hepatitis C virus; glecaprevir; pibrentasvir; retreatment; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; LIVER-BIOPSY; GENOTYPE; HCV; FIBROSIS;
D O I
10.3390/biomedicines8040074
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glecaprevir/pibrentasvir (G/P) are direct-acting antivirals (DAAs) that achieve a high sustained virological response (SVR) rate for hepatitis C virus (HCV) infection. We investigated G/P effectiveness for HCV patients based on real-world experience and the clinical features of retreatment cases. HCV patients (n = 182) were compared for clinical features and outcomes between first treatment (n = 159) and retreatment (n = 23) G/P groups. Overall, 77 patients (42.3%) were male, the median age was 68 years, and 86/66/1/4 cases had genotype 1/2/1 + 2/3, respectively. An SVR was achieved in 97.8% (178/182) of cases by intention-to-treat analysis and 99.4% (178/179) of cases by per-protocol analysis. There were no remarkable differences between the first treatment and retreatment groups for male (42.8% vs. 39.1%, p = 0.70), median age (68 vs. 68 years, p = 0.36), prior hepatocellular carcinoma (5.8% vs. 8.7%, p = 0.59), or the fibrosis markers AST-to-platelet ratio index (APRI) (0.5 vs. 0.5, p = 0.80) and fibrosis-4 (FIB-4) index (2.2 vs. 2.6, p = 0.59). The retreatment group had a significantly more frequent history of interferon treatment (12.3% vs. 52.2%, p < 0.01) and the Y93H mutation (25.0% vs. 64.7%, p = 0.02). The number of retreatment patients who had experienced 3, 2, and 1 DAA treatment failures was 1, 3, and 19, respectively, all of whom ultimately achieved an SVR by G/P treatment. In conclusion, G/P was effective and safe for both HCV first treatment and retreatment cases despite the retreatment group having specific resistance mutations for other prior DAAs. As G/P treatment failure has been reported for P32 deletions, clinicians should consider resistance mutations during DAA selection.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection
    Toyoda, Hidenori
    Atsukawa, Masanori
    Watanabe, Tsunamasa
    Nakamuta, Makoto
    Uojima, Haruki
    Nozaki, Akito
    Takaguchi, Koichi
    Fujioka, Shinichi
    Iio, Etsuko
    Shima, Toshihide
    Akahane, Takehiro
    Fukunishi, Shinya
    Asano, Toru
    Michitaka, Kojiro
    Tsuji, Kunihiko
    Abe, Hiroshi
    Mikami, Shigeru
    Okubo, Hironao
    Okubo, Tomomi
    Shimada, Noritomo
    Ishikawa, Toru
    Moriya, Akio
    Tani, Joji
    Morishita, Asahiro
    Ogawa, Chikara
    Tachi, Yoshihiko
    Ikeda, Hiroki
    Yamashita, Naoki
    Yasuda, Satoshi
    Chuma, Makoto
    Tsutsui, Akemi
    Hiraoka, Atsushi
    Ikegami, Tadashi
    Genda, Takuya
    Tsubota, Akihito
    Masaki, Tsutomu
    Tanaka, Yasuhito
    Iwakiri, Katsuhiko
    Kumada, Takashi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (05) : 855 - 861
  • [42] Glecaprevir/Pibrentasvir for the Treatment of Patients with Chronic Hepatitis C Virus Infection: Updated Real-World Data from the German Hepatitis C-Registry
    Wiegand, Johannes
    Naumann, Uwe
    Stoehr, Albrecht
    Sick, Christoph
    John, Christine
    Teuber, Gerlinde
    Schiffelholz, Willibold, Sr.
    Mauss, Stefan
    Lohmann, Kristina
    Koenig, Bettina
    Pangerl, Andreas
    Simon, Karl-Georg
    HEPATOLOGY, 2018, 68 : 364A - 364A
  • [43] Real-World Effectiveness and Safety of Glecaprevir plus Pibrentasvir in HCV: Postmarketing Observational Data from Switzerland
    Mullhaupti, Beat
    Semela, David
    Ruckstuhl, Lisa
    Magenta, Lorenzo
    Clerc, Olivier
    Torgler, Ralph
    Negro, Francesco
    Semmo, Nasser
    SWISS MEDICAL WEEKLY, 2019, : 7S - 7S
  • [44] CLINICAL AND VIROLOGICAL CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS C AND FAILURE TO A GLECAPREVIR AND PIBRENTASVIR (G/P) TREATMENT IN REAL WORLD
    Garcia Garcia, Federico
    Dietz, Julia
    Di Maio, Velia Chiara
    Vermehren, Johannes
    De Salazar, Adolfo
    Paolucci, Stefania
    Mullhaupt, Beat
    Coppola, Nicola
    Cabezas, Joaquin
    Stauber, Rudolf E.
    Puoti, Massimo
    Arenas Ruiz-Tapiador, Juan Ignacio
    Aragri, Marianna
    Jimenez, Miguel
    Callegaro, Annapaola
    Pascasio Acevedo, Juan Manuel
    Macias Rodriguez, Manuel Alberto
    Rosales Zabal, Jose Miguel
    Micheli, Valeria
    Gomez, Neus
    Tellez, Francisco
    Sarrazin, Christoph
    Silberstein, Francesca Ceccherini
    HEPATOLOGY, 2019, 70 : 998A - 999A
  • [45] Real-world safety, effectiveness, and patient-reported outcomes in patients with chronic hepatitis C virus infection treated with glecaprevir/pibrentasvir: Data from the German Hepatitis C-Registry
    Cornberg, Markus
    Stoehr, Albrecht
    Uwe, Naumann
    Klinker, Hartwig
    Thomas, Lutz
    Schiffelholz, Willibold
    Qurishi, Nazifa
    Pangerl, Andreas
    Lohmann, Kristina
    Koenig, Bettina
    Simon, Karl-Georg
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E45 - E45
  • [46] Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures
    Mitsutaka Osawa
    Michio Imamura
    Yuji Teraoka
    Takuro Uchida
    Kei Morio
    Hatsue Fujino
    Takashi Nakahara
    Atsushi Ono
    Eisuke Murakami
    Tomokazu Kawaoka
    Daiki Miki
    Masataka Tsuge
    Akira Hiramatsu
    Hiroshi Aikata
    C. Nelson Hayes
    Kazuaki Chayama
    Journal of Gastroenterology, 2019, 54 : 291 - 296
  • [47] Effectiveness of 8 weeks of glecaprevir/pibrentasvir in treatment-naive hepatitis C patients with liver cirrhosis: results from the real-world Spanish Hepa-C registry
    Turnes, Juan
    Hernandez-Guerra, Manuel
    Souto Rodriguez, Raquel
    Fernandez, Inmaculada
    Carrion, Jose A.
    de Cuenca Moron, Beatriz
    Manuel Pascasio, Juan
    Moreno Planas, Jose Maria
    Moreno, Jose Juan
    Bellot, Pau
    Delgado, Manuel
    Salmeron, Javier
    Marino, Zoe
    Rosales Zabal, Jose Miguel
    Garcia-Samaniego Rey, Francisco Javier
    Morillas, Rosa
    Diago, Moises
    Crespo, Javier
    Gonzalez Santiago, Jesus
    Mateos Munoz, Beatriz
    Torras, Xavier
    Badia-Aranda, Esther
    Bonet, Lucia
    Menendez, Fernando
    Bernal Monterde, Vanesa
    Marquez Rodriguez, Paqui
    Arenas, Juan
    Prieto, Martin
    Perez Cachafeiro, Santiago
    JOURNAL OF HEPATOLOGY, 2020, 73 : S346 - S347
  • [48] The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study
    Akito Nozaki
    Masanori Atsukawa
    Chisa Kondo
    Hidenori Toyoda
    Makoto Chuma
    Makoto Nakamuta
    Haruki Uojima
    Koichi Takaguchi
    Hiroki Ikeda
    Tsunamasa Watanabe
    Shintaro Ogawa
    Norio Itokawa
    Taeang Arai
    Atsushi Hiraoka
    Toru Asano
    Shinichi Fujioka
    Tadashi Ikegami
    Toshihide Shima
    Chikara Ogawa
    Takehiro Akahane
    Noritomo Shimada
    Shinya Fukunishi
    Hiroshi Abe
    Akihito Tsubota
    Takuya Genda
    Hironao Okubo
    Shigeru Mikami
    Asahiro Morishita
    Akio Moriya
    Joji Tani
    Yoshihiko Tachi
    Naoki Hotta
    Toru Ishikawa
    Takeshi Okanoue
    Yasuhito Tanaka
    Takashi Kumada
    Katsuhiko Iwakiri
    Shin Maeda
    Hepatology International, 2020, 14 : 225 - 238
  • [49] Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis
    Lampertico, Pietro
    Carrion, Jose A.
    Curry, Michael
    Turnes, Juan
    Cornberg, Markus
    Negro, Francesco
    Brown, Ashley
    Persico, Marcello
    Wick, Nicole
    Porcalla, Ariel
    Pangerl, Andreas
    Crown, Eric
    Larsen, Lois
    Yu, Yao
    Wedemeyer, Heiner
    JOURNAL OF HEPATOLOGY, 2020, 72 (06) : 1112 - 1121
  • [50] Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts
    Feld, Jordan J.
    Forns, Xavier
    Dylla, Douglas E.
    Kumada, Hiromitsu
    de Ledinghen, Victor
    Wei, Lai
    Brown, Robert S., Jr.
    Flisiak, Robert
    Lampertico, Pietro
    Thabut, Dominique
    Bondin, Mark
    Tatsch, Fernando
    Burroughs, Margaret
    Marcinak, John
    Zhang, Zhenzhen
    Emmett, Amanda
    Jacobson, Ira M.
    JOURNAL OF VIRAL HEPATITIS, 2022, 29 (12) : 1050 - 1061